Sanofi Pays Regeneron $1 Billion Upfront to Expand Dupixent Alliance in Deal Worth Up to $8 Billion

SentiSense · Published · Updated

Sanofi will pay Regeneron $1 billion upfront, plus up to $7 billion in milestones, to add four Regeneron-invented long-acting immunology antibodies to...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis